Core Laboratories N.V.
New York Stock ExchangeTotal Valuation
Core Laboratories N.V. carries a market capitalization of 578.05M, placing it among publicly traded companies globally. Its enterprise value stands at 683.03M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 578.05M |
| Enterprise Value | 683.03M |
Share Statistics
Core Laboratories N.V. currently has 45.88M shares outstanding.
| Shares Outstanding | 45.88M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Core Laboratories N.V. trades at a trailing price-to-earnings ratio of 21.82. The price-to-sales ratio is 1.02, and the price-to-book ratio stands at 1.96.
| PE Ratio | 21.82 |
| PS Ratio | 1.02 |
| PB Ratio | 1.96 |
| P/TBV Ratio | 3.34 |
| P/FCF Ratio | 19.27 |
| P/OCF Ratio | 18.83 |
Enterprise Valuation
On an enterprise value basis, Core Laboratories N.V. trades at an EV/EBITDA multiple of 12.20 and an EV/FCF ratio of 19.19. The EV/Sales ratio of 1.32 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 16.61 provides insight into valuation relative to core operating earnings.
| EV / Sales | 1.32 |
| EV / EBITDA | 12.20 |
| EV / EBIT | 16.61 |
| EV / FCF | 19.19 |
Financial Position
Core Laboratories N.V. maintains a current ratio of 2.12, meaning it holds 2.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 59.23, indicating elevated leverage, while an interest coverage ratio of 5.09 demonstrates adequate ability to service its debt obligations.
| Current Ratio | 2.12 |
| Quick Ratio | 1.37 |
| Debt / Equity | 59.23 |
| Debt / EBITDA | 2.95 |
| Interest Coverage | 5.09 |
Financial Efficiency
Core Laboratories N.V. posts a return on equity of 9.12 and a return on invested capital of 6.19.
| Return on Equity (ROE) | 9.12 |
| Return on Assets (ROA) | 4.10 |
| Return on Invested Capital (ROIC) | 6.19 |
| Return on Capital Employed (ROCE) | 7.06 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 7.35 |
Taxes
Over the trailing twelve months, Core Laboratories N.V. has paid 12.10M in income taxes, reflecting an effective tax rate of 32.89.
| Income Tax | 12.10M |
| Effective Tax Rate | 32.89 |
Stock Price Statistics
Core Laboratories N.V.'s stock has gained approximately 1.04754% over the past 52 weeks. The 50-day moving average sits at 11.66, while the 200-day moving average is 15.02.
| Beta (5Y) | N/A |
| 52-Week Price Change | 1.04754% |
| 50-Day Moving Average | 11.66 |
| 200-Day Moving Average | 15.02 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Core Laboratories N.V. generated 519.18M in revenue and converted that into 24.35M in net income, yielding earnings per share of 0.53. EBITDA reached 55.97M, while operating income came in at 41.11M.
| Revenue | 519.18M |
| Gross Profit | 86.47M |
| Operating Income | 41.11M |
| Pretax Income | 36.80M |
| Net Income | 24.35M |
| EBITDA | 55.97M |
| EBIT | 41.11M |
| Earnings Per Share (EPS) | 0.53 |
Balance Sheet
Core Laboratories N.V. holds 22.74M in cash and equivalents against 165.12M in total debt, resulting in a net debt position of 91.13M. Total book value stands at 272.67M, with working capital of 113.31M providing operational flexibility.
| Cash & Cash Equivalents | 22.74M |
| Total Debt | 165.12M |
| Net Debt | 91.13M |
| Equity (Book Value) | 272.67M |
| Book Value Per Share | 5.94 |
| Working Capital | 113.31M |
Cash Flow
Core Laboratories N.V. produced 28.22M in operating cash flow over the past twelve months.
| Operating Cash Flow | 28.22M |
| Capital Expenditures | N/A |
| Free Cash Flow | 28.22M |
| FCF Per Share | 0.62 |
Margins
Core Laboratories N.V. operates with a gross margin of 16.66, reflecting its pricing power and cost economics. The operating margin of 7.92 and net profit margin of 4.69 provide insight into operational efficiency.
| Gross Margin | 16.66 |
| Operating Margin | 7.92 |
| Pretax Margin | 7.09 |
| Profit Margin | 4.69 |
| EBITDA Margin | 10.78 |
Dividends & Yields
The company's payout ratio of 7.39 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.04 |
| Dividend Yield | N/A |
| Payout Ratio | 7.39 |
| Shareholder Yield | 5.24 |
| FCF Yield | 5.19 |
Stock Splits
Core Laboratories N.V.'s most recent stock split took place on July 9, 2010 with a 1:2 split ratio.
| Last Split Date | 7/9/2010 |
| Split Ratio | 1:2 |
Scores
Core Laboratories N.V. posts an Altman Z-Score of 3.23, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 3.23 |